Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL).

Trial Profile

Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL).

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2013

At a glance

  • Drugs Asparaginase (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 11 Feb 2011 Planned end date changed from 1 Mar 2008 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top